AI Engines For more Details: Perplexity Kagi Labs You
Antifungal Activity: Tolnaftate works by inhibiting the growth and reproduction of fungi, including dermatophytes such as Trichophyton, Epidermophyton, and Microsporum species. It disrupts the fungal cell membrane, leading to cell death and eventual eradication of the infection.
Treatment of Athlete's Foot: Athlete's foot is a common fungal infection that affects the skin between the toes and on the soles of the feet. Tolnaftate is effective in treating athlete's foot by relieving symptoms such as itching, burning, cracking, and scaling of the skin.
Treatment of Jock Itch: Jock itch, also known as tinea cruris, is a fungal infection that affects the groin and inner thighs. Tolnaftate can be used to alleviate symptoms of jock itch, including redness, itching, and rash in the affected area.
Treatment of Ringworm: Ringworm is a fungal infection that can occur on the skin, scalp, or nails, characterized by circular, red, scaly lesions. Tolnaftate is effective in treating ringworm infections of the skin (tinea corporis) by reducing inflammation and eliminating the fungus responsible for the infection.
Topical Application: Tolnaftate is typically available in topical formulations such as creams, powders, sprays, and solutions. It is applied directly to the affected area of the skin, usually two to three times daily, until the infection resolves.
Low Risk of Side Effects: Tolnaftate is generally well-tolerated when used as directed. Common side effects may include mild skin irritation, redness, itching, or burning at the application site. Serious side effects are rare but may include allergic reactions or worsening of the fungal infection.
Avoidance of Eye and Mucous Membrane Contact: Tolnaftate should not be applied to the eyes, mouth, or mucous membranes. In case of accidental contact, the affected area should be rinsed thoroughly with water.
Complete Treatment Course: It is important to complete the full course of treatment with tolnaftate, even if symptoms improve before the infection has cleared completely. Failure to complete the treatment course may result in recurrence of the fungal infection.
Prevention of Spread: To prevent the spread of fungal infections and recurrence, patients should practice good hygiene, keep the affected area clean and dry, avoid sharing personal items such as towels or clothing, and wear clean socks and shoes.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.2 | 0.3 | 13 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.1 | 2 | 0.55 |
| Allergies | 5.4 | 2.4 | 1.25 |
| Allergy to milk products | 2 | 1.6 | 0.25 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.6 | 6.9 | -0.05 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.9 | 0.9 | 2.22 |
| Ankylosing spondylitis | 4 | 1.2 | 2.33 |
| Anorexia Nervosa | 1.6 | 2.9 | -0.81 |
| Antiphospholipid syndrome (APS) | 1.9 | 0.3 | 5.33 |
| Asthma | 4.6 | 2.1 | 1.19 |
| Atherosclerosis | 2.5 | 1.5 | 0.67 |
| Atrial fibrillation | 3.8 | 2.7 | 0.41 |
| Autism | 8.4 | 8.6 | -0.02 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.6 | 2.6 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1 | 1 | |
| Cancer (General) | 0.9 | 2.2 | -1.44 |
| Carcinoma | 4.7 | 2.6 | 0.81 |
| Celiac Disease | 3.4 | 3.1 | 0.1 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 4.6 | 6.8 | -0.48 |
| Chronic Kidney Disease | 3.7 | 2.7 | 0.37 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.5 | 1.7 | 0.47 |
| Chronic Urticaria (Hives) | 1.8 | 0.9 | 1 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1.3 | 0.38 |
| Cognitive Function | 3 | 1.6 | 0.88 |
| Colorectal Cancer | 8 | 2.6 | 2.08 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 2.5 | 3 | -0.2 |
| COVID-19 | 8.9 | 10 | -0.12 |
| Crohn's Disease | 9.2 | 5.2 | 0.77 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1 | 1.4 | -0.4 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 2.6 | 1.4 | 0.86 |
| Denture Wearers Oral Shifts | 1.3 | 1.3 | |
| Depression | 10.5 | 9.3 | 0.13 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 1.8 | 0.11 |
| Endometriosis | 3.3 | 2.2 | 0.5 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.9 | 2 | 0.95 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 2.8 | 2.1 | 0.33 |
| Functional constipation / chronic idiopathic constipation | 5.9 | 4.2 | 0.4 |
| gallstone disease (gsd) | 3.9 | 1.2 | 2.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 0.8 | 2 |
| Generalized anxiety disorder | 2.7 | 1.6 | 0.69 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.3 | 0.6 | 1.17 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.7 | -0.89 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4 | 1.5 | 1.67 |
| Heart Failure | 3.8 | 2 | 0.9 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.8 | 0.6 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.2 | 3.5 |
| hyperglycemia | 2 | 1.4 | 0.43 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.6 | 4.3 | 0.07 |
| Hypothyroidism | 0.1 | 0.7 | -6 |
| Hypoxia | 3.5 | 0.3 | 10.67 |
| IgA nephropathy (IgAN) | 1.6 | 3.7 | -1.31 |
| Inflammatory Bowel Disease | 7.1 | 8.9 | -0.25 |
| Insomnia | 2.2 | 2.4 | -0.09 |
| Intelligence | 1.8 | 0.2 | 8 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 7.9 | 5.3 | 0.49 |
| ischemic stroke | 2.6 | 1.7 | 0.53 |
| Liver Cirrhosis | 6.9 | 4.9 | 0.41 |
| Long COVID | 6 | 6.8 | -0.13 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.2 | 1.2 | 0 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 0.6 | 2.2 | -2.67 |
| ME/CFS without IBS | 0.8 | 2.4 | -2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.2 | 0.6 | 1 |
| Metabolic Syndrome | 7.8 | 7.2 | 0.08 |
| Mood Disorders | 9.7 | 7.5 | 0.29 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 6.4 | 5.9 | 0.08 |
| Multiple system atrophy (MSA) | 0.9 | 0.7 | 0.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 1.8 | -1.8 | |
| Neuropathy (all types) | 0.5 | 1.6 | -2.2 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5 | 3.7 | 0.35 |
| NonCeliac Gluten Sensitivity | 1.2 | 0.6 | 1 |
| Obesity | 9.4 | 8.2 | 0.15 |
| obsessive-compulsive disorder | 5.7 | 3.7 | 0.54 |
| Osteoarthritis | 2.4 | 1.3 | 0.85 |
| Osteoporosis | 2.2 | 1.5 | 0.47 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 8.1 | 6.9 | 0.17 |
| Polycystic ovary syndrome | 7.4 | 3.2 | 1.31 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 2.5 | 2.8 | -0.12 |
| Psoriasis | 3.8 | 3.1 | 0.23 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.2 | 4.7 | 0.53 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 5.4 | 2.9 | 0.86 |
| scoliosis | 0.7 | 0.6 | 0.17 |
| Sjögren syndrome | 2.3 | 2.8 | -0.22 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 1.3 | 0.3 | 3.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.1 | 0.1 | 20 |
| Stress / posttraumatic stress disorder | 3.1 | 2.3 | 0.35 |
| Systemic Lupus Erythematosus | 4.3 | 2.2 | 0.95 |
| Tic Disorder | 1.5 | 1.3 | 0.15 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.6 | 3.1 | 0.48 |
| Type 2 Diabetes | 8.5 | 7.5 | 0.13 |
| Ulcerative colitis | 6 | 6.4 | -0.07 |
| Unhealthy Ageing | 5.1 | 2.5 | 1.04 |
| Vitiligo | 2.2 | 1.5 | 0.47 |
